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Abstract: Magnetic resonance imaging (MRI) of glioblastoma multiforme (GBM) with 
molecular imaging agents would allow for the specific localization of brain tumors. Prior 
studies using T1-weighted MR imaging demonstrated that the SBK2-Tris-(Gd-DOTA)3 
molecular imaging agent labeled heterotopic xenograft models of brain tumors more intensely 
than non-specific contrast agents using conventional T1-weighted imaging techniques.  
In this study, we used a dynamic quantitative T1 mapping strategy to more objectively 
compare intra-tumoral retention of the SBK2-Tris-(Gd-DOTA)3 agent over time in 
comparison to non-targeted control agents. Our results demonstrate that the targeted  
SBK2-Tris-(Gd-DOTA)3 agent, a scrambled-Tris-(Gd-DOTA)3 control agent, and the  
non-specific clinical contrast agent Optimark™ all enhanced flank tumors of human glioma 
cells with similar maximal changes on T1 mapping. However, the retention of the agents 
differs. The non-specific agents show significant recovery within 20 min by an increase in 
T1 while the specific agent SBK2-Tris-(Gd-DOTA)3 is retained in the tumors and shows little 
recovery over 60 min. The retention effect is demonstrated by percent change in T1 values 
and slope calculations as well as by calculations of gadolinium concentration in tumor 
compared to muscle. Quantitative T1 mapping demonstrates the superior binding and 
retention in tumors of the SBK2-Tris-(Gd-DOTA)3 agent over time compared to the  
non-specific contrast agent currently in clinical use. 
Keywords: magnetic resonance imaging; molecular imaging; T1 relaxation time;  
cancer imaging; tumor detection; protein tyrosine phosphatase; PTPmu 
 
1. Introduction 
While various imaging modalities are used in clinical and surgical settings, magnetic resonance 
imaging (MRI) is the preferred method of brain tumor imaging prior to surgery. The benefits of MRI 
include excellent delineation of anatomic detail and multiple available soft tissue contrast mechanisms. 
To improve MRI assessments of tumors, targeted molecular contrast agents are in development to 
provide biological specificity in identifying and distinguishing the irregular and indistinct tumor margins 
of invasive cancers [1,2]. A typical goal for molecular contrast agents is to bind preferentially to 
molecules specific to the tumor in comparison to the surrounding normal tissue. Therefore, molecules 
that are enriched in the tumor microenvironment are ideal targets. 
Glioblastoma multiforme (GBM) is a highly aggressive tumor that arises in the brain. Patients with GBM 
survive, on average, one year post-diagnosis [3] despite undergoing surgery, radiation, and 
chemotherapy. The devastating nature of GBM is due to the highly dispersive and invasive tumor cells 
that infiltrate the brain and migrate away from the main tumor mass. These distant, migratory cells, often 
undetectable by conventional MRI methods, make complete surgical resection difficult [4]. The receptor 
protein tyrosine phosphatase PTPµ is a transmembrane protein that is proteolyzed in tumor tissue to 
yield an extracellular fragment and a membrane-freed intracellular fragment [5,6]. The proteolyzed 
extracellular fragment of PTPµ accumulates in aggressive GBM tumors and provides a detectable moiety 
for molecular imaging [7].  
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We have previously developed a molecular imaging agent that specifically binds to the PTPµ extracellular 
fragment, called SBK2 that is linked to a fluorophore, and labels both the main GBM tumor mass [5] 
and greater than 99% of the dispersing cells up to 3.5 mm away from the main tumor [7]. When conjugated 
to a gadolinium (Gd) chelate as an MRI contrast agent, the SBK2-Tris-(Gd-DOTA)3 agent showed greater 
contrast enhancement than the non-specific agent, ProHance, when intravenously injected into mice bearing 
heterotopic flank tumors of human glioma cells using conventional T1-weighted MR imaging [8]. The 
SBK2-Tris-(Gd-DOTA)3 agent labeled the tumors within 5 min with a high level of contrast persisting 
for 2 h post injection, significantly higher than ProHance® alone [8]. One limitation of these prior studies 
is that conventional T1-weighted imaging techniques rely on relative signal intensity changes over time 
and are inherently qualitative at each time point. The T1-weighted values of a given region of interest are 
relative to the values from another area. For example, a comparison of tumor to adjacent muscle at that 
particular time point is represented as a contrast to noise value for a particular time point. Therefore 
despite these promising initial results, a rigorously quantitative approach was needed to determine the 
in vivo binding and retention properties of the SBK2-Tris-(Gd-DOTA)3 agent in comparison to controls 
over time. 
In contrast to T1-weighted imaging, T1 relaxation time mapping is a quantitative approach that allows 
measurement of T1 values. When acquired dynamically, these T1 relaxation time values allow each time point 
to be objectively, quantitatively, and longitudinally compared within a single agent as well as among 
different agents. Furthermore, T1 mapping limits the impact of scanner dependent variation. Quantitative 
T1 measurements can then be used to calculate contrast agent concentration within each imaging voxel 
(volume element). This technique is especially important for molecular imaging where the goal is to 
relate regions of accumulating and/or retained contrast agent to the location of specific disease markers. We 
hypothesized that T1 mapping could be performed to quantitatively determine contrast agent concentration 
in tumors as well as evaluate successful specific targeting by contrast agents. Therefore, we conducted a 
series of experiments comparing the SBK2-Tris-(Gd-DOTA)3 agent to the scrambled-Tris-(Gd-DOTA)3 
control as well as a non-specific clinical contrast agent, Optimark™, in mice bearing heterotopic flank 
tumors of human LN-229 glioma cells. In this study, we dynamically evaluated the extent and duration 
of tumor enhancement following contrast administration with T1 mapping. We observed that all of the 
contrast agents achieve similar levels of initial T1 reductions indicating similar delivery to the tumor region 
between 10 to 15 min after injection. Notably, a large and statistically significant difference was observed in 
the retention of the specific SBK2-Tris-(Gd-DOTA)3 agent versus the non-specific agents at later time 
points. We conclude that when evaluating and comparing MR molecular imaging agents, evaluation of 
retention time as determined with T1 mapping is a robust indicator of agent specificity. 
2. Methods and Materials 
All reagents were used without further purification unless otherwise stated. Optimark™ was  
purchased from Mallinckrodt Pharmaceuticals (St. Louis, MO, USA), and saline was obtained from 
Hospira, Inc. (Lake Forest, IL, USA). The Fmoc-protected amino acids, 2-chlorotrityl chloride resin, 
and benzotriazol-1-yl-oxy-tris-(pyrrolidino) phosphonium hexafluorophosphate (PyBOP) used for 
peptide synthesis were purchased from Chem-Impex International, Inc. (Wood Dale, IL, USA), along 
with anhydrous N,N-diisopropylethyl amine (DIPEA), trifluoroacetic acid (TFA), 1,2-diethanethiol, 
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triisopropylsilane and piperidine from Sigma-Aldrich (St. Louis, MO, USA). N,N-dimethylformamide 
(DMF), and dichloromethane were purchased from Fisher Scientific (Pittsburgh, PA, USA). Anhydrous 
1-hydroxybenzotriazole (HOBt) was obtained from Apex Bio Technology (Houston, TX, USA). The 
detailed syntheses of maleimido-tris-propargyl [9] and azido-(Gd-DOTA) [10] have been described 
previously. Gadolinium (III) acetate tetrahydrate was from Strem Chemicals (Newburyport, MA, USA). 
2.1. Synthesis and Characterization of SBK2-Tris-(Gd-DOTA)3 and  
Scrambled-Tris-(Gd-DOTA)3 Agents 
The syntheses and characterization of SBK2-Tris-(Gd-DOTA)3 and scrambled-Tris-(Gd-DOTA)3 
agents have been described previously [8]. Briefly, the peptides were synthesized using conventional 
solid-phase synthetic methods and FMOC-protected amino acids. Peptide purity was assessed using  
LC-MS/MS on a Thermo Finnigan LTQ Linear ion trap mass spectrometer with a Phenomenex Jupiter C18 
reversed-phase capillary chromatography column. Peptides were conjugated to maleimido-tris-propargyl by 
reacting the N-terminal cysteine with the maleimide group. A copper-catalyzed azide-alkyne cycloaddition 
reaction was then used to couple azido-(Gd-DOTA) to the free alkyne groups of the tris-propargyl peptides. 
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF; Autoflex Speed, Bruker Corp., 
Billerica, MA, USA) was used to monitor the conjugation reaction of azido-(Gd-DOTA) to the peptide-
tris-propargyl moieties. Gadolinium (Gd) content was measured using inductively coupled plasma 
optical emission spectroscopy (ICP-OES) (Agilent 730 Axial ICP-OES; Agilent Technologies, 
Wilmington, DE, USA). T1 relaxation constants for the agents were measured on the Bruker Biospec 
9.4T MRI scanner (Bruker Corp., Billerica, MA, USA) at 37 °C. 
2.2. Cell Culture and Flank Tumor Implants 
The human LN-229 glioma cell line was purchased from American Type Culture Collection 
(Manassas, VA, USA) and cultured in DMEM medium supplemented with 5% fetal bovine serum. Cells 
were infected with lentivirus encoding green fluorescent protein (GFP) and stable cultures were 
established. The cells were diluted in a 1:1 mixture of PBS and BD Matrigel™ Matrix (BD Biosciences, 
Franklin Lakes, NJ, USA), and injected into the right flank of both male and female nude athymic mice  
(NCr-nu/+, NCr-nu/nu, 20–25 g each) as previously described [5]. Each flank was implanted with  
2 × 106 cells. To correlate tumor position with GFP fluorescence, mice were imaged using the  
Perkin-Elmer Maestro™ FLEX In Vivo Imaging System as previously described [5].  
2.3. Molecular Imaging of Tumors with MRI 
The MRI study was performed using a Bruker Biospec 9.4 T preclinical MRI scanner (Bruker Corp., 
Billerica, MA, USA) with a 35 mm inner diameter mouse body radio frequency (RF) coil. Mice  
bearing LN-229 flank tumors were imaged at 2–5 weeks post tumor implant. Polyurethane tubing  
(0.014″ ID × 0.033″ OD) (SAI Infusion Technologies, Lake Villa, IL, USA) was connected to a 1 mL 
syringe and loaded with the appropriate amount of a given contrast agent dissolved or diluted in saline. 
All agents were administered an equal Gd concentration of 0.2 mmol·Gd/kg. The total volume of each 
agent injected was <100 μL, with an additional 50 μL of saline used to flush the line and ensure that the 
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full dose was administered to the animal. After mice were anesthetized with a 2%  
isoflurane-oxygen mixture in an isoflurane induction chamber, tail veins were catheterized with a  
26 gauge veterinary catheter and connected to the pre-loaded tubing described above. The animals were 
moved into the magnet and kept under inhalation anesthesia with 1.5% isoflurane-oxygen via a nose 
cone. A respiratory sensor connected to a monitoring system (SA Instruments, Stony Brook, NY, USA) 
was placed on the back of the animal to monitor rate and depth of respiration. Body temperature was 
maintained at 35 ± 1 °C by blowing warm air into the magnet through a feedback control system. A 
group of 5–6 mice was used for each agent.  
High-resolution T2-weighted images were first obtained for each mouse using a RARE  
(Rapid Acquisition with Relaxation Enhancement) acquisition (TR/TE = 5000/40 ms, 20 slices,  
resolution = 0.117 × 0.117 × 0.5 mm) to select the imaging slice for the dynamic T1 mapping  
acquisition [11]. The dynamic T1 data were then acquired using a snapshot GRE (Gradient Recalled 
Echo) acquisition with inversion recovery preparation described previously [12,13] (10 inversion times 
(263, 775, 1287, 1799, 2311, 2823, 3335, 3847, 4359, and 4871 ms), GRE imaging readout  
TR/TE = 4.0 ms/1.3 ms, flip angle = 10 degrees, resolution = 0.234 × 0.234 × 1 mm, Field of View  
(FOV) = 30 × 30 mm, and 10 signal averages). The total acquisition for each T1 mapping scan  
was 2.5 min. After five baseline/pre-injection T1 mapping scans, Optimark™, the targeted  
SBK2-Tris-(Gd-DOTA)3 agent, or the non-targeted scrambled-Tris-(Gd-DOTA)3 control was injected at a 
dose of 0.2 mmol of Gd/kg followed by a 50 µL flush of saline. T1 maps were then consecutively acquired 
every 2.5 min over 62.5 min. 
2.4. Calculation of T1 Mapping Values, Gd Concentration, and Slope Analysis 
The MRI data were imported into MATLAB enabling estimation of both pixel-wise T1 relaxation 
time maps as well as mean intra-tumoral T1 changes using an ROI analysis. The T1 maps were obtained from 
the T1 mapping acquisition using previously described methods based on mono-exponential models [13]. 
To compare the multiple imaging agents, the pre- and post-contrast T1 maps were then used to calculate 
maps of % change in T1, which is directly related to the concentration of each agent within the tumor. 
To calculate Gd concentrations, T1 relaxivity constants determined at 9.4T were used along with  
T1 map values. 
As the T1 maps and T2-weighted images were co-registered, the ROI analysis was performed by manually 
drawing the ROI on the T2-weighted images. The same ROI was then applied to all of the  
T1 mapping images and the average value in the ROI was calculated as a measure of tumor uptake of 
each imaging agent. Plots of normalized T1 values in the tumor were calculated by dividing the  
post-contrast injection T1 maps by an average of the 5 baseline (pre-contrast injection) tumor T1 values. 
This normalization was performed to limit the effects of variation in the pre-contrast tumor T1 values on 
the comparison of the molecular imaging agents. 
As an imaging marker for contrast agent retention, a slope analysis was performed on the  
normalized T1 values. Slopes were calculated for Optimark™, scrambled-Tris-(Gd-DOTA)3, and  
SBK2-Tris-(Gd-DOTA)3 by using all of the mean tumor T1 values from 15 to 60 min following agent 
administration. For each pair of contrast agents, normalized T1 map values at each time point, along with 
the slopes of post-contrast T1 curves were evaluated for statistical significance using a two-tailed Student’s 
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t-test, assuming statistical significance at p < 0.05. An F-test was also used to determine if the variance 
was significantly different between the two samples being compared. 
3. Results 
3.1. Quantitative MRI Contrast Agent Evaluation 
To evaluate the efficacy of the specific agent, SBK2-Tris-(Gd-DOTA)3, we compared this targeted 
agent to the scrambled-Tris-(Gd-DOTA)3, and the non-specific conventional clinical contrast agent 
Optimark™. We acquired and analyzed 2D axial T1 mapping images in GFP-positive LN-229 human 
glioma flank tumors heterotopically implanted in athymic (nu/nu) mice at 2–5 weeks post-implantation. 
Five T1 maps of the tumor region were acquired before injection of contrast agents to serve as baseline 
measurements, and then at 2.5 min intervals for 62.5 min following intravenous injection of Optimark™, 
scrambled-Tris-(Gd-DOTA)3, or SBK2-Tris-(Gd-DOTA)3 agents administered at a dose of 0.2 mmol·Gd/kg. 
Representative fluorescence and MRI images of mice with the implanted flank tumors are shown in 
Figure 1 for each contrast agent. Using optical imaging, the physical outline of the flank tumors is evident 
under brightfield illumination (Figure 1) and the GFP-positive LN-229 glioma cells are also clearly 
visible in the fluorescence images (Figure 1). For MR imaging, the axial T2-weighted images (Figure 1) 
are shown with the regions of interest (ROIs) indicated by dashed lines that were used for T1 mapping. 
In this view, the flank tumors are clearly visible in the T2-weighted images allowing for accurate ROI 
selection. Figure 1 also shows T1-weighted images acquired from the T1 mapping acquisitions both at 
baseline (Figure 1) and 15 min following contrast agent injection (Figure 1), respectively. All three contrast 
agents showed significant contrast uptake as evidenced by the relative change in the T1-weighted images. 
However, a rigorous quantitative comparison is not possible with these T1-weighted images. 
3.2. Quantitative T1 Mapping of MRI Contrast Agent Efficacy in Heterotopic Glioma Flank Tumors 
To obtain a quantitative comparison of the difference in tumor enhancement over time between the 
three contrast agents, T1 mapping was employed to compare the changes in T1 relaxation times in the tumor 
for each contrast agent over time. Pixel-wise maps of T1 relaxation time were normalized to the mean 
baseline T1 values and are shown as heat maps overlaying the corresponding gray scale axial images for 
the indicated time points in Figure 2. The color-coded scale bar indicates the normalized  
T1 relaxation time from lowest (blue) to highest (red). As expected, all of the contrast agents resulted in 
a reduction in T1 relaxation time within the first 15 min after agent injection. Importantly, by 30 min 
post-injection, both the Optimark™ and scrambled-Tris-(Gd-DOTA)3 agents had started to clear from 
the tumor while the targeted SBK2-Tris-(Gd-DOTA)3 contrast agent was retained within the tumor as 
evidenced by the limited change in T1 relaxation time relative to that observed at 15 min post-injection 
(Figure 2). At one-hour post-injection, the normalized T1 relaxation time had returned to ~60% of the  
pre-contrast values for both Optimark™ and scrambled-Tris-(Gd-DOTA)3 agents (Figure 2). 
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Figure 1. The SBK2-Tris-(Gd-DOTA)3 molecular imaging agent and the non-specific  
agents all enhance LN-229 tumors. Representative brightfield image of GFP-positive  
LN-229 flank tumors for animals where 0.2 mmol Gd/kg of Optimark™,  
scrambled-Tris-(Gd-DOTA)3, or SBK2-Tris-(Gd-DOTA)3 was administered. N = 6 for 
Optimark™, N = 5 for scrambled-Tris-(Gd-DOTA)3, and N = 5 for SBK2-Tris-(Gd-DOTA)3. 
GFP fluorescence image of LN-229 tumor cells for each of the three contrast agents.  
T2 low-resolution images with Region of Interest (ROI), illustrated by a dashed red line, 
show the tumor area used for T1 map quantification in Figures 2–4. Axial T1-weighted images 
of LN-229 flank tumor at baseline (before injection of contrast agents) and at time of 
maximum contrast (15 min) following intravenous injection. 
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Figure 2. The specific molecular imaging agent SBK2-Tris-(Gd-DOTA)3 results in prolonged 
decrease in T1 relaxation time in tumors compared to non-specific agents. Normalized  
T1 maps of the flank tumors overlaid onto T1-weighted images at pre-contrast (0 min);  
15 min post-injection; 30 min post-injection; and 60 min post-injection. The color-coded 
scale bar indicates normalized T1 relaxation time values with dark blue representing the lowest 
T1 values resulting from the T1 shortening effect of the contrast agents. Note the prolonged 
decrease in normalized T1 values with the SBK2-Tris-(Gd-DOTA)3 agent resulting in lower 
T1 map values while the T1 values of the non-specific agents have returned to about 60%  
of baseline. 
To evaluate the retention of the agents in greater detail, we plotted the mean tumor normalized  
T1 values for groups of mice administered each contrast agent over the entire scanning session of  
62.5 min. We found that the mean tumor normalized T1 values of all three agents showed maximal 
decreases in T1 between 10 and 15 min following injection (Figure 3). Importantly, the normalized  
T1 values for the SBK2-Tris-(Gd-DOTA)3 agent remain reduced over the entire 62.5 min scanning 
session (Figure 3), while the scrambled-Tris-(Gd-DOTA)3 and Optimark™ normalized T1 mapping 
values begin to return towards baseline levels starting at approximately 20 min. Normalized T1 values 
are significantly different between SBK2-Tris-(Gd-DOTA)3 and Optimark™ from 30–62.5 min (ranges 
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from p < 0.001 to p < 0.04 depending upon the time point), and between SBK2-Tris-(Gd-DOTA)3 and 
scrambled-Tris-(Gd-DOTA)3 from 17.5–62.5 min (ranges from p < 0.002 to p < 0.03). The normalized  
T1 values for the Optimark™ and scrambled-Tris-(Gd-DOTA)3 agents were not significantly different at 
any time point. The rate of contrast agent clearance from the tumor was calculated by determining the change 
in mean tumor normalized T1 over time from 15 to 60 min for each agent. The recovery slopes of  
scrambled-Tris-(Gd-DOTA)3 and Optimark™ were not statistically different from one another.  
In contrast, the slope of SBK2-Tris-(Gd-DOTA)3 recovery differed significantly from that of both  
scrambled-Tris-(Gd-DOTA)3 (p < 0.01) and Optimark™ (p < 0.0002) demonstrating quantitatively that 
SBK2-Tris-(Gd-DOTA)3 is specifically retained in the flank tumors over time. 
 
Figure 3. Mean tumor normalized T1 values and slope analysis following intravenous 
administration of Optimark™, scrambled-Tris-(Gd-DOTA)3, or SBK2-Tris-(Gd-DOTA)3 
contrast agents in cohorts of nu/nu athymic mice bearing glioma flank tumors  
administered at a dose of 0.2 mmol·Gd/kg. Note the sustained decrease in normalized T1 for 
SBK2-Tris-(Gd-DOTA)3 as well as the significant difference in slope due to agent clearance 
between the non-specific agents compared to SBK2-Tris-(Gd-DOTA)3, which showed the 
highest retention. N = 6 for Optimark™, N = 5 for scrambled-Tris-(Gd-DOTA)3, and N = 5 
for SBK2-Tris-(Gd-DOTA)3. Data plotted as means ± standard error. (A) Mean tumor 
normalized T1 values at baseline and after agent injection measured every 2.5 min for 62.5 min. 
Normalized T1 values are significantly different between SBK2-Tris-(Gd-DOTA)3 and 
Optimark™ from 30–62.5 min (ranges from p < 0.001 to p < 0.04 depending upon the time 
point), and between SBK2-Tris-(Gd-DOTA)3 and scrambled-Tris-(Gd-DOTA)3 from  
17.5–62.5 min (ranges from p < 0.002 to p < 0.03). Optimark™ and scrambled-Tris-(Gd-DOTA)3 
were not significantly different at any time point. (B) The slopes of the lines were determined 
between 15 and 60 min post-injection to examine the rate of agent clearance. The slope of 
SBK2-Tris-(Gd-DOTA)3 recovery was significantly different than that of both Optimark™ 
(p < 0.0002) and scrambled-Tris-(Gd-DOTA)3 (p < 0.01). The slopes of Optimark™ and 
scrambled-Tris-(Gd-DOTA)3 were not significantly different from one another. 
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To complement the data presented in Figures 2 and 3, maps of the percent change in T1 values were 
also calculated at multiple time points for the flank tumors (Figure 4). Baseline (pre-contrast) values are 
shown in Figure 4 and are near zero, as expected. As anticipated, the percent change in T1 at  
15 min post-injection is dramatically increased for all three agents (Figure 4). 
 
Figure 4. Maps of percent change in T1 relaxation time for flank tumors overlaid onto axial 
T1-weighted images plotted at pre-contrast (0 min); 15 min post-injection; 30 min  
post-injection; and 60 min post-injection. The percent change in T1 values demonstrate that 
the agent SBK2-Tris-(Gd-DOTA)3 is retained in the tumor for a longer period of time than 
either Optimark™ or scrambled-Tris-(Gd-DOTA)3 agents. The color scale indicates percent 
change in T1 relaxation time on a 0%–80% scale. 
By 30 min, the percent change in T1 is showing some initial reduction for the Optimark™ and 
scrambled-Tris-(Gd-DOTA)3 agents, while the percent change in T1 for the SBK2-Tris-(Gd-DOTA)3 
remains essentially unchanged from that at 15 min (Figure 4). By 60 min post-injection, the percent change 
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in T1 values for Optimark™ and scrambled-Tris-(Gd-DOTA)3-treated animals is closer to that observed at 
baseline. In contrast, percent change in T1 values in the animal administered SBK2-Tris-(Gd-DOTA)3 
remains virtually unchanged in comparison to the 15 and 30 min time points (Figure 4). 
A second group of heterotopic glioma flank tumor bearing mice with larger tumors were also 
administered Optimark™, scrambled-Tris-(Gd-DOTA)3, and SBK2-Tris-(Gd-DOTA)3 agents as shown 
in Figure 5 with enlarged images. These images show the non-heterogeneous labeling of the tumors by 
the non-specific agents, whereas the SBK2-Tris-(Gd-DOTA)3 agent uniformly recognizes the entire 
tumor. The “rim” or “edge” effect of the non-specific agents is often seen in clinical imaging [14].  
A similar result demonstrating this “rim” effect for non-specific agents was also observed in our previous 
studies [8]. In contrast, the SBK2-Tris-(Gd-DOTA)3 agent exhibits remarkable uniformity across the 
entire tumor consistent with binding of the PTPµ fragment within the tumors rather than in just the tumor 
(neo)vasculature. 
 
Figure 5. Maps representing the percent change in T1 values indicates that the tumors  
of mice at pre-contrast (0 min); 15 min post-injection; 30 min post-injection; and 60 min  
post-injection show SBK2-Tris-(Gd-DOTA)3 is retained for a much longer period of time 
than Optimark™ and scrambled-Tris-(Gd-DOTA)3 agents even in larger tumors. Note also 
that the T1 changes at 30 min and 60 min for the SBK2-Tris-(Gd-DOTA)3 agent are uniformly 
distributed throughout the tumor while the non-specific agents show rim enhancement typical 
of conventional agents. The color scale indicates percent change in T1 relaxation time on a 
0%–80% scale. 
A significant benefit of T1 mapping analysis is that this quantitative imaging method allows for the 
calculation of contrast agent concentration in any region of interest. As shown in Figure 6, the Gd content 
in tumors of animals treated with the specific SBK2-Tris-(Gd-DOTA)3 agent remains at peak levels even 
an hour after treatment while clearance begins to occur before 30 min in the animals treated with the 
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non-specific agents. As expected, the Gd concentration in control areas of muscle is much lower than 
that of tumor (Figure 6B). 
 
Figure 6. Gadolinium concentrations in tumor and muscle of animals treated with different 
contrast agents. (A) Maps of gadolinium concentration overlaid onto axial T1-weighted  
images plotted at pre-contrast (0 min); 10 min post-injection; 15 min post-injection; 30 min 
post-injection; and 60 min post-injection. Consistent with T1 map values observed for the 
non-specific contrast agents, Gd concentrations are highest at 10 and 15 min in tumors of 
animals treated with Optimark™ and scrambled-Tris-(Gd-DOTA)3, and then rapidly decrease 
at later time points. Gd concentration in tumor of animal receiving SBK2-Tris-(Gd-DOTA)3 
remains at near peak levels at 60 min indicating retention of the agent in the tumor.  
(B) Mean gadolinium concentrations ± SE are plotted for tumor and muscle for groups of 
animals treated with the indicated contrast agents at different time points. Gd concentrations 
in tumors of animals treated with Optimark™ and scrambled-Tris-(Gd-DOTA)3 are highest 
at 10 and 15 min after injection and then decline. In contrast, the Gd concentration in tumors 
of animals treated with SBK2-Tris-(Gd-DOTA)3 persist at approximately 0.15 mM from  
10 to 60 min. Gd concentrations calculated in control muscle regions (hatched bars) are 
substantially lower than those in tumors. 
4. Discussion and Conclusion 
We dynamically evaluated the extent and duration of tumor enhancement following contrast administration 
with T1 mapping. Our study using T1 mapping to evaluate the efficacy of the SBK2-Tris-(Gd-DOTA)3 
molecular imaging agent in flank GBM tumors demonstrates that SBK2-Tris-(Gd-DOTA)3 is effective 
at specifically recognizing and binding GBM tumors compared to non-targeted contrast agents. Three 
major findings come to light as a result of our study. 
The first major finding is that the T1 mapping method can be used to dynamically measure T1 values 
and determine Gd-based contrast agent concentration over time in tumors using molecular imaging agents. 
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We observed that all of the contrast agents achieve similar levels of initial reductions in T1 relaxation 
times indicating comparable delivery to the tumor region between 10 to 15 min after injection. Notably, 
a large and statistically significant difference was observed in the duration of the reduction in T1 relaxation 
time and the retention of the specific SBK2-Tris-(Gd-DOTA)3 agent versus the non-specific agents. 
Whereas the T1 relaxation times for the non-specific contrast agents more rapidly returned towards their 
respective pre-contrast levels, the T1 relaxation times for the SBK2-Tris-(Gd-DOTA)3 agent remained 
close to the maximum change in T1 relaxation for the entire hour of imaging (Figures 2 and 3). Importantly, 
T1 mapping provides improved quantification in comparison to conventional T1-weighted imaging.  
In T1-weighted imaging, the accumulation of contrast agent is associated with increased signal intensity 
in the T1-weighted images due to the T1 relaxation time reductions imposed by the contrast agent. 
Unfortunately, the signal intensity changes detected in T1-weighted imaging studies are not quantitative 
in nature as these signals are also impacted by many other factors including variation in the excitation 
and detection efficiency of the MRI coils of different scanners. Therefore, quantitative T1-weighted imaging 
studies require modeling of the signal intensity profile. As a result, the individual time points in a  
T1-weighted study are only qualitative by nature. As shown herein, dynamic T1 mapping provides 
quantitative assessments at each imaging time point providing the opportunity to assess both the delivery 
and retention of the contrast agents (i.e., minimum T1 relaxation time; maximal change in T1) as shown 
in Figure 3. These data demonstrate the utility of quantitative T1 mapping as opposed to conventional 
T1-weighted imaging in objectively quantifying the ability of a targeted molecular agent to label tumors 
and allows for the calculation of clearance rates among different agents. 
The second major finding is that T1 mapping allowed us to determine that the extent of initial contrast 
is approximately the same regardless of agent specificity. Tumor imaging research often focuses on the 
enhanced permeability and retention (EPR) effect that is observed in tumor tissue due to pathophysiological 
changes in the vasculature and host environment that promotes the leakage of large macromolecules 
(>40 kD to 800 kD) into tumor tissue while simultaneously slowing the clearance of macromolecules 
through the lymphatic system [15]. The initial delivery of these molecules is due to the enhanced permeability 
of the vessels in tumors, which is supported by our data. Gd-chelates are small molecules that passively 
leak from the circulation into the extracellular fluid [16]. Due to their small size, Gd-chelates also rapidly 
diffuse back into the vasculature [17]. An actively targeted small molecular weight contrast agent 
conjugated to Gd, on the other hand, that specifically binds and recognizes a molecular target should be 
retained [16,18]. 
Our third major finding is consistent with the idea of prolonged tumor retention being exhibited  
only by specifically targeted agents such as SBK2-Tris-(Gd-DOTA)3. Our data show that  
SBK2-Tris-(Gd-DOTA)3, but not the non-specific agents Optimark™ and scrambled-Tris-(Gd-DOTA)3 
produced a sustained decrease in T1 map values. As shown in Figure 3, we observed similar initial 
contrast due to the passive diffusion of Gd-chelates into tumor tissue. This corresponds to the greatest 
change in normalized T1 map values at 10 min obtained for the non-specific contrast agents that then 
rapidly return to baseline over the course of the hour. In our tumor model, the mean normalized T1 map 
or numerical value for passive targeting, occurring at 10 min, is between 0.30 for Optimark™ and  
0.35 for scrambled-Tris-(Gd-DOTA)3. For SBK2-Tris-(Gd-DOTA)3, on the other hand, the normalized  
T1 map values stabilized at approximately the same maximal decrease for as long as the tumors were 
imaged, over the course of an hour. Furthermore, T1 mapping allows Gd concentration to be calculated.  
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As shown in Figure 6, Gd concentrations reached maximal levels in tumors of animals treated with  
non-specific contrast agents between 10 and 15 min post-injection before decreasing, while Gd 
concentration in the tumors of SBK2-Tris-(Gd-DOTA)3-treated animals persisted at near maximal 
concentrations for the hour of imaging. The SBK2-Tris-(Gd-DOTA)3 agent binds specifically to PTPµ 
fragments present in glioma tumors [5,8]. Therefore, in this heterotopic tumor model, the retention of 
the agent within the tumor results from the specific in vivo binding to PTPµ fragments. Since all three 
contrast agents lower T1 map values to a similar extent, but differ dramatically in the period of increased 
Gd concentration and duration of reduced T1 map values in tumor, these data suggest that measurement 
of agent concentration and retention within this 30–60 min time frame is a powerful tool with which to 
assess specific recognition of a disease state. 
Importantly, the T1 mapping technique is easily translated into evaluation of molecular imaging agents 
using conventional clinical scanners. We hypothesize that the increased retention of SBK2-Tris-(Gd-DOTA)3 
in tumors will allow detection of smaller tumors as the sustained reduction in T1 values will provide the 
opportunity to acquire T1 maps at high resolution, which requires these longer acquisition times. 
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